Home > Insider Trading > Filing (0001070081-20-000003)

Filing Details

Accession Number:: 0001070081-20-000003
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-01-06 16:52:59
Reporting Period:: 2020-01-02

Accepted Time:: 2020-01-06 16:52:59
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1070081	Ptc Therapeutics Inc.	PTCT	Pharmaceutical Preparations (2834)	043416587

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1707685	Marie Christine Utter	C/O Ptc Therapeutics, Inc. 100 Corporate Court South Plainfield NJ 07080	Svp, Finance & Cao	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-01-02	2,362	$11.23	7,946	No	4	M	Direct
Common Stock	Disposition	2020-01-02	2,362	$47.89	5,584	No	4	S	Direct
Common Stock	Acquisiton	2020-01-03	788	$11.23	6,372	No	4	M	Direct
Common Stock	Disposition	2020-01-03	788	$47.42	5,584	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right To Buy)	Disposition	2020-01-02	2,362	$11.23	2,362	$11.23
Common Stock	Stock Option (Right To Buy)	Disposition	2020-01-03	788	$11.23	788	$11.23

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,938		2027-01-02	No	4	M	Direct
3,150		2027-01-02	No	4	M	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (Right To Buy)	$490.80	2021-04-27	74	74	Direct
Common Stock	Stock Option (Right To Buy)	$218.40	2022-01-10	21	21	Direct
Common Stock	Stock Option (Right To Buy)	$40.45	2024-09-23	4,688	4,688	Direct
Common Stock	Stock Option (Right To Buy)	$51.00	2025-01-02	17,800	17,800	Direct
Common Stock	Stock Option (Right To Buy)	$30.86	2026-01-03	10,310	10,310	Direct
Common Stock	Stock Option (Right To Buy)	$13.10	2027-06-02	6,250	6,250	Direct
Common Stock	Stock Option (Right To Buy)	$18.01	2028-01-02	30,000	30,000	Direct
Common Stock	Stock Option (Right To Buy)	$33.02	2029-01-21	42,500	42,500	Direct
Common Stock	Stock Option (Right To Buy)	$33.02	2029-01-21	10,100	10,100	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2021-04-27	74	74	Direct
2022-01-10	21	21	Direct
2024-09-23	4,688	4,688	Direct
2025-01-02	17,800	17,800	Direct
2026-01-03	10,310	10,310	Direct
2027-06-02	6,250	6,250	Direct
2028-01-02	30,000	30,000	Direct
2029-01-21	42,500	42,500	Direct
2029-01-21	10,100	10,100	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 29, 2019.
Includes 371 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2019 and 276 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2019.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.55 to $48.46 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
Currently exercisable.
This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.